1. Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107-11 DOI: 10.1016/j.drugpo.2017.06.010.
2. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183-8 DOI: 10.1016/j.drugpo.2019.01.010.
3. CDC. Opioid overdose, understanding the epidemic. 2021 [updated March 19, 2020. Available from: https://www.cdc.gov/drugoverdose/epidemic/index.html.
4. Somerville NJ, O'Donnell J, Gladden RM, Zibbell JE, Green TC, Younkin M, et al. Characteristics of fentanyl overdose - Massachusetts, 2014-2016. MMWR Morb Mortal Wkly Rep. 2017;66(14):382-6 DOI: 10.15585/mmwr.mm6614a2.
5. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419-27 DOI: 10.15585/mmwr.mm675152e1.
6. Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts NCHS. 2021.
7. CDC. Overdose deaths accelerating during COVID-19: expanded prevention efforts needed. 2020 [Available from: https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html.
8. Association AM. Issue brief: drug overdose epidemic worsened during COVID pandemic 2021 [updated June 1, 2021.
9. Slavova S, Rock P, Bush HM, Quesinberry D, Walsh SL. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020;214:108176 DOI: 10.1016/j.drugalcdep.2020.108176.
10. CDC NCfHS, Office of Communication Drug overdose deaths in the U.S. top 100,000 annually for immediate release: November 17, 2021. 2021 [Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm.
11. Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999-2017. NCHS Data Brief. 2018(329):1-8.
12. Health MDoP. Data brief: opioid-related overdose: deaths among Massachusetts residents 2021 [Available from: https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-may-2021/download.
13. Singh VM, Browne T, Montgomery J. The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis. Public Health Rep. 2020;135(1):6-10 DOI: 10.1177/0033354919887741.
14. Lyden J, Binswanger IA. The United States opioid epidemic. Semin Perinatol. 2019;43(3):123-31 DOI: 10.1053/j.semperi.2019.01.001.
15. Glick JL, Christensen T, Park JN, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: results from a multi-site study. Drug Alcohol Depend. 2019;194:527-32 DOI: 10.1016/j.drugalcdep.2018.10.017.
16. Sherman SG, Park, J. N., McKenzie, M., Morales, K., Christensen, T., & Green, T. C. FORECAST study summary report John Hopkins Bloomberg School of Public Health.; 2018.
17. Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59-66 DOI: 10.1016/j.drugpo.2018.10.001.
18. Goldman JE, Waye KM, Periera KA, Krieger MS, Yedinak JL, Marshall BDL. Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. Harm Reduct J. 2019;16(1):3 DOI: 10.1186/s12954-018-0276-0.
19. Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122-8 DOI: 10.1016/j.drugpo.2018.08.007.
20. Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J. 2018;15(1):46 DOI: 10.1186/s12954-018-0252-8.
21. Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661 DOI: 10.1016/j.drugpo.2020.102661.
22. Ciccarone D, Ondocsin J, Mars SG. Heroin uncertainties: exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'. Int J Drug Policy. 2017;46:146-55 DOI: 10.1016/j.drugpo.2017.06.004.
23. Marshall BDL, Krieger MS, Yedinak JL, Ogera P, Banerjee P, Alexander-Scott NE, et al. Epidemiology of fentanyl-involved drug overdose deaths: a geospatial retrospective study in Rhode Island, USA. Int J Drug Policy. 2017;46:130-5 DOI: 10.1016/j.drugpo.2017.05.029.
24. Ti L, Tobias S, Lysyshyn M, Laing R, Nosova E, Choi J, et al. Detecting fentanyl using point-of-care drug checking technologies: a validation study. Drug Alcohol Depend. 2020;212:108006 DOI: 10.1016/j.drugalcdep.2020.108006.
25. Vandergrift GW, Gill CG. Paper spray mass spectrometry: a new drug checking tool for harm reduction in the opioid overdose crisis. J Mass Spectrom. 2019;54(9):729-37 DOI: 10.1002/jms.4431.
26. Harper L, Powell J, Pijl EM. An overview of forensic drug testing methods and their suitability for harm reduction point-of-care services. Harm Reduct J. 2017;14(1):52 DOI: 10.1186/s12954-017-0179-5.
27. MX908TM. 908 Devices Inc. Boston, Massachusetts. [
28. Rapid ResponseTM. BTNX Corporation, Canada. [
29. Tupper KW, McCrae K, Garber I, Lysyshyn M, Wood E. Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242-5 DOI: 10.1016/j.drugalcdep.2018.06.020.
30. Krieger MS, Goedel WC, Buxton JA, Lysyshyn M, Bernstein E, Sherman SG, et al. Use of rapid fentanyl test strips among young adults who use drugs. Int J Drug Policy. 2018;61:52-8 DOI: 10.1016/j.drugpo.2018.09.009.
31. Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019;68:46-53 DOI: 10.1016/j.drugpo.2019.03.003.
32. Rhodes B, Costenbader B, Wilson L, Hershow R, Carroll J, Zule W, et al. Urban, individuals of color are impacted by fentanyl-contaminated heroin. Int J Drug Policy. 2019;73:1-6 DOI: 10.1016/j.drugpo.2019.07.008.
33. Fogger SA. Methamphetamine use: a new wave in the opioid crisis? J Addict Nurs. 2019;30(3):219-23 DOI: 10.1097/jan.0000000000000298.
34. Hainer R. Polysubstance use and stimulants: a dangerous fourth wave in the opioid crisis. Boston Medical Center: HealthCity Newsletter 2019.
35. Jenkins R. The fourth wave of the US opioid epidemic and its implications for the rural US: a federal perspective Preventive Medicine. In press.
36. Beletsky L, Davis CS. Today's fentanyl crisis: Prohibition's Iron Law, revisited. Int J Drug Policy. 2017;46:156-9 DOI: 10.1016/j.drugpo.2017.05.050.
37. Foglia R, Kline A, Cooperman NA. New and emerging opioid overdose risk factors. Curr Addict Rep. 2021:1-11 DOI: 10.1007/s40429-021-00368-6.
38. Barratt MJ, Bruno R, Ezard N, Ritter A. Pill testing or drug checking in Australia: Acceptability of service design features. Drug Alcohol Rev. 2018;37(2):226-36 DOI: 10.1111/dar.12576.
39. Karamouzian M, Papamihali K, Graham B, Crabtree A, Mill C, Kuo M, et al. Known fentanyl use among clients of harm reduction sites in British Columbia, Canada. Int J Drug Policy. 2020;77:102665 DOI: 10.1016/j.drugpo.2020.102665.
40. Stein MD, Kenney SR, Anderson BJ, Bailey GL. Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use. J Subst Abuse Treat. 2019;104:144-7 DOI: 10.1016/j.jsat.2019.07.006.
41. Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: Perceptions and use of an evolving drug in Baltimore, MD. J Psychoactive Drugs. 2018;50(2):167-76 DOI: 10.1080/02791072.2017.1394508.
42. Daniulaityte R, Carlson RR, Juhascik MP, Strayer KE, Sizemore IE. Street fentanyl use: Experiences, preferences, and concordance between self-reports and urine toxicology. Int J Drug Policy. 2019;71:3-9 DOI: 10.1016/j.drugpo.2019.05.020.